Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.

Wojdacz TK, Amarasinghe HE, Kadalayil L, Beattie A, Forster J, Blakemore SJ, Parker H, Bryant D, Larrayoz M, Clifford R, Robbe P, Davis ZA, Else M, Howard DR, Stamatopoulos B, Steele AJ, Rosenquist R, Collins A, Pettitt AR, Hillmen P, Plass C, Schuh A, Catovsky D, Oscier DG, Rose-Zerilli MJJ, Oakes CC, Strefford JC.

Blood Adv. 2019 Aug 27;3(16):2474-2481. doi: 10.1182/bloodadvances.2019000237.

2.

A unique genome in EBV-positive BL.

Strefford JC, Oscier DG.

Blood. 2019 Mar 21;133(12):1269-1270. doi: 10.1182/blood-2019-01-897603. No abstract available.

PMID:
30898773
3.

CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

Parker H, McIver-Brown NR, Davis ZA, Parry M, Rose-Zerilli MJJ, Xochelli A, Gibson J, Walewska R, Strefford JC, Oscier DG.

Blood Adv. 2018 May 22;2(10):1116-1119. doi: 10.1182/bloodadvances.2018019760. No abstract available.

4.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

5.

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.

Larrayoz M, Rose-Zerilli MJ, Kadalayil L, Parker H, Blakemore S, Forster J, Davis Z, Steele AJ, Collins A, Else M, Catovsky D, Oscier DG, Strefford JC.

Leukemia. 2017 Feb;31(2):510-514. doi: 10.1038/leu.2016.298. Epub 2016 Oct 26. No abstract available.

6.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

7.

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease.

Rose-Zerilli MJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, Larrayoz M, McCarthy H, Walewska R, Forster J, Gardiner A, Steele AJ, Chelala C, Ennis S, Collins A, Oakes CC, Oscier DG, Strefford JC.

Leukemia. 2016 Jun;30(6):1301-10. doi: 10.1038/leu.2016.10. Epub 2016 Feb 5.

8.

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Strefford JC, Kadalayil L, Forster J, Rose-Zerilli MJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, Parker H, Stankovic T, Pepper C, Fegan C, Baird D, Collins A, Catovsky D, Oscier DG.

Leukemia. 2015 Dec;29(12):2411-4. doi: 10.1038/leu.2015.217. Epub 2015 Aug 10. No abstract available.

9.

Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, Davies Z, Steele AJ, Parker H, Cross NC, Oscier DG, Strefford JC.

Haematologica. 2015 Jun;100(6):e237-9. doi: 10.3324/haematol.2014.120238. Epub 2015 Feb 20. No abstract available.

10.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF.

J Clin Oncol. 2014 Apr 20;32(12):1236-41. doi: 10.1200/JCO.2013.49.6547. Epub 2014 Mar 17.

11.

ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Rose-Zerilli MJ, Forster J, Parker H, Parker A, Rodríguez AE, Chaplin T, Gardiner A, Steele AJ, Collins A, Young BD, Skowronska A, Catovsky D, Stankovic T, Oscier DG, Strefford JC.

Haematologica. 2014 Apr;99(4):736-42. doi: 10.3324/haematol.2013.098574. Epub 2014 Feb 28.

12.

Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.

Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC.

PLoS One. 2013 Dec 13;8(12):e83244. doi: 10.1371/journal.pone.0083244. eCollection 2013.

13.

CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.

Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner LJ, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR.

Blood. 2013 Dec 19;122(26):4253-8. doi: 10.1182/blood-2013-07-516666. Epub 2013 Oct 15.

14.

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC.

Blood. 2013 Jan 17;121(3):468-75. doi: 10.1182/blood-2012-05-429282. Epub 2012 Oct 18.

15.

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR.

Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6.

16.

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies.

Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, Davis Z, van Gastel-Mol EJ, Tresoldi C, Chu CC, Cahill N, Giudicelli V, Tichy B, Pedersen LB, Foroni L, Bonello L, Janus A, Smedby K, Anagnostopoulos A, Merle-Beral H, Laoutaris N, Juliusson G, di Celle PF, Pospisilova S, Jurlander J, Geisler C, Tsaftaris A, Lefranc MP, Langerak AW, Oscier DG, Chiorazzi N, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K.

Blood. 2012 May 10;119(19):4467-75. doi: 10.1182/blood-2011-11-393694. Epub 2012 Mar 13.

17.

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.

Knight SJ, Yau C, Clifford R, Timbs AT, Sadighi Akha E, Dréau HM, Burns A, Ciria C, Oscier DG, Pettitt AR, Dutton S, Holmes CC, Taylor J, Cazier JB, Schuh A.

Leukemia. 2012 Jul;26(7):1564-75. doi: 10.1038/leu.2012.13. Epub 2012 Jan 19.

18.

Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage.

Britt-Compton B, Lin TT, Ahmed G, Weston V, Jones RE, Fegan C, Oscier DG, Stankovic T, Pepper C, Baird DM.

Leukemia. 2012 Apr;26(4):826-30. doi: 10.1038/leu.2011.281. Epub 2011 Oct 11. No abstract available.

PMID:
21986843
19.

ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.

Skowronska A, Austen B, Powell JE, Weston V, Oscier DG, Dyer MJ, Matutes E, Pratt G, Fegan C, Moss P, Taylor MA, Stankovic T.

Haematologica. 2012 Jan;97(1):142-6. doi: 10.3324/haematol.2011.048827. Epub 2011 Sep 20.

20.

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, Beers SA, French RR, Cox KL, Davies AJ, Potter KN, Mockridge CI, Oscier DG, Johnson PW, Cragg MS, Glennie MJ.

Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.

21.

Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial.

Wade R, Di Bernardo MC, Richards S, Rossi D, Crowther-Swanepoel D, Gaidano G, Oscier DG, Catovsky D, Houlston RS.

Haematologica. 2011 Oct;96(10):1496-503. doi: 10.3324/haematol.2011.043471. Epub 2011 Jun 9.

22.

13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia.

Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, Griffiths M, Collins A, Young BD, Oscier DG, Strefford JC.

Leukemia. 2011 Mar;25(3):489-97. doi: 10.1038/leu.2010.288. Epub 2010 Dec 10.

PMID:
21151023
23.

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

Majid A, Lin TT, Best G, Fishlock K, Hewamana S, Pratt G, Yallop D, Buggins AG, Wagner S, Kennedy BJ, Miall F, Hills R, Devereux S, Oscier DG, Dyer MJ, Fegan C, Pepper C.

Leuk Res. 2011 Jun;35(6):750-6. doi: 10.1016/j.leukres.2010.10.022. Epub 2010 Nov 18.

PMID:
21093051
24.

Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.

Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G.

Epigenetics. 2011 Mar;6(3):300-6. Epub 2011 Mar 1.

25.

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T.

Blood. 2010 Nov 25;116(22):4578-87. doi: 10.1182/blood-2010-01-265769. Epub 2010 Aug 25.

26.

Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.

Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, Hervé M, Meffre E, Oscier DG, Vlassara H, Scofield RH, Chen Y, Allen SL, Kolitz J, Rai KR, Chu CC, Chiorazzi N.

Mol Med. 2008 Nov-Dec;14(11-12):665-74. doi: 10.2119/2008-00102.Catera. Epub 2008 Sep 25.

27.

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, Dyer MJ, Oscier DG.

Leukemia. 2009 Jan;23(1):212-4. doi: 10.1038/leu.2008.260. Epub 2008 Sep 25. No abstract available.

PMID:
18818700
28.

A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer MJ, Oscier DG.

Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17. No abstract available.

PMID:
18200038
30.

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.

Sellick GS, Wade R, Richards S, Oscier DG, Catovsky D, Houlston RS.

Blood. 2008 Feb 1;111(3):1625-33. Epub 2007 Nov 15.

31.

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.

Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R.

Clin Cancer Res. 2007 Sep 1;13(17):5048-55.

32.

Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis.

Amato D, Oscier DG, Davis Z, Mould S, Zheng J, Kolomietz E, Wang C.

Am J Clin Pathol. 2007 Aug;128(2):333-8.

PMID:
17638670
33.

Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1-69.

Walewska R, Majid A, Davis Z, Dusanjh P, Kennedy DB, Oscier DG, Dyer MJ.

Leukemia. 2007 Dec;21(12):2537-8. Epub 2007 Jun 28. No abstract available.

PMID:
17597803
34.

ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis.

Best OG, Ibbotson RE, Parker AE, Davis ZA, Orchard JA, Oscier DG.

Cytometry B Clin Cytom. 2006 Jul 15;70(4):235-41.

35.

Guidelines on the management of Waldenström macroglobulinaemia.

Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG; Haemato-Oncology Task Force of the British Committee for Standards in Haematology.

Br J Haematol. 2006 Mar;132(6):683-97. Review. No abstract available.

PMID:
16487169
36.

Splenic marginal zone lymphoma: 7q abnormalities.

Ibbotson RE, Parker AE, Oscier DG.

Methods Mol Med. 2005;115:241-50.

PMID:
15998972
37.

Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.

Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF.

Clin Lymphoma. 2005 Mar;5(4):294-7.

PMID:
15794869
38.

Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.

Sonoki T, Willis TG, Oscier DG, Karran EL, Siebert R, Dyer MJ.

Leukemia. 2004 Dec;18(12):2026-31.

PMID:
15496980
39.

DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse.

Corcoran MM, Hammarsund M, Zhu C, Lerner M, Kapanadze B, Wilson B, Larsson C, Forsberg L, Ibbotson RE, Einhorn S, Oscier DG, Grandér D, Sangfelt O.

Genes Chromosomes Cancer. 2004 Aug;40(4):285-97.

PMID:
15188451
40.

Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.

Grand EK, Grand FH, Chase AJ, Ross FM, Corcoran MM, Oscier DG, Cross NC.

Genes Chromosomes Cancer. 2004 May;40(1):78-83.

PMID:
15034873
41.

Novel technique to facilitate the rapid identification of CLL patients utilising the VH3-21 gene.

Davis ZA, Ibbotson RE, Wiseman CM, Oscier DG.

Leukemia. 2004 Apr;18(4):872. No abstract available.

PMID:
14961039
42.

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.

Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG.

Lancet. 2004 Jan 10;363(9403):105-11.

PMID:
14726163
43.

Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms.

Davis ZA, Orchard JA, Corcoran MM, Oscier DG.

Blood. 2003 Oct 15;102(8):3075. No abstract available.

44.

P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12.

Zhang LY, Ibbotson RE, Orchard JA, Gardiner AC, Seear RV, Chase AJ, Oscier DG, Cross NC.

Leukemia. 2003 Nov;17(11):2097-100.

PMID:
12931211
45.

Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B.

Boyd RS, Adam PJ, Patel S, Loader JA, Berry J, Redpath NT, Poyser HR, Fletcher GC, Burgess NA, Stamps AC, Hudson L, Smith P, Griffiths M, Willis TG, Karran EL, Oscier DG, Catovsky D, Terrett JA, Dyer MJ.

Leukemia. 2003 Aug;17(8):1605-12.

PMID:
12886250
46.

Human chromosome 7: DNA sequence and biology.

Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Döhner H, Döhner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC.

Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.

47.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.

Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.

48.

The optimal management of polycythaemia vera.

McMullin MF, Bareford D, Craig J, Green AR, Harrison C, Oscier DG, Reilly JT; Myeloproliferative Disorders (UK) Study Group.

Br J Haematol. 2003 Feb;120(3):543-4; author reply 544-5. No abstract available.

PMID:
12580978
49.

The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.

Cragg MS, Chan HT, Fox MD, Tutt A, Smith A, Oscier DG, Hamblin TJ, Glennie MJ.

Blood. 2002 Nov 1;100(9):3068-76.

50.

Supplemental Content

Loading ...
Support Center